Fig. 3: Time to castration-resistance and overall survival by starting treatment in mHSPC – Kaplan-Meier method.

AAP abiraterone acetate plus prednisone, ADT androgen deprivation therapy, APA apalutamide, DTX docetaxel, ENZ enzalutamide, mHSCP metastatic hormone-sensitive prostate cancer.